- Conditions
- Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate Cancer
- Interventions
- Atezolizumab, Tocilizumab, Etrumadenant
- Drug
- Lead sponsor
- David Oh
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 2
- States / cities
- San Francisco, California • St Louis, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 60
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Prostate Cancer, Prostatic Adenocarcinoma
- Interventions
- degarelix injection, androgen deprivation therapy
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Carcinoma, Squamous Cell
- Interventions
- JNJ-90301900 (NBTXR3), Cetuximab, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Duarte, California • La Jolla, California + 23 more
- Conditions
- Prostate Cancer
- Interventions
- Intratumoral (IT) Poly ICLC 0.5 mg, Intratumoral (IT) Poly ICLC 1.0 mg, Intramuscular (IM) Poly ICLC, Radical Prostatectomy
- Biological · Procedure
- Lead sponsor
- Ashutosh Kumar Tewari
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostatectomy
- Interventions
- Small Urethral Bite Technique, Large Urethral Bite Technique
- Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Erectile Dysfunction Following Radical Prostatectomy, Urinary Incontinence of Non-organic Origin
- Interventions
- Viberect device
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 40 Years to 70 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Frederick, Maryland
- Conditions
- Bladder Cancer
- Interventions
- cisplatin, fluorouracil, paclitaxel, radiation therapy, Gemcitabine, Radical cystectomy
- Drug · Radiation · Procedure
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- Up to 120 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2018
- U.S. locations
- 2
- States / cities
- Salt Lake City, Utah
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- TAR-200
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Dalton, Georgia • Hanover, Maryland + 5 more
- Conditions
- Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma, Pelvic Malignancy, Bladder Transitional Cell Carcinoma, Bladder Neoplasm
- Interventions
- Ureteral Stent Placement, No Ureteral Stent, Indocyanine Green with Fluorescence Imaging
- Procedure · Diagnostic Test
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Recurrent Renal Cell Carcinoma, Stage I Renal Cell Cancer, Stage II Renal Cell Cancer
- Interventions
- Laboratory Biomarker Analysis, Nephrectomy, Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003
- Other · Procedure · Biological
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Voiding Disorders
- Interventions
- Simultaneous functional MRI and urodynamic studies, Questionnaires, Post Void Residual (PVR), Uroflow and Bladder Diary, Urinalysis
- Diagnostic Test · Behavioral · Other
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 45 Years to 90 Years · Male only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Surgery
- Interventions
- Continuous Noninvasive Hemoglobin Monitoring
- Device
- Lead sponsor
- Society for the Advancement of Blood Management, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 5
- States / cities
- Stanford, California • The Bronx, New York • Durham, North Carolina + 2 more
- Conditions
- Bladder Cancer
- Interventions
- Alvimopan, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Bladder Cancer
- Interventions
- Stent placement, Alvimopan
- Procedure · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Bladder Carcinoma, Refractory Bladder Carcinoma, Urinary Tract Infection
- Interventions
- Clindamycin, Diary, Ertapenem, Levofloxacin, Nitrofurantoin, Trimethoprim-Sulfamethoxazole
- Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Ovarian Neoplasms, Endometrial Cancer, Endometrial Neoplasm
- Interventions
- BMX-001, Paclitaxel (Taxol)
- Drug
- Lead sponsor
- BioMimetix JV, LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Stem Cell Transplantation, Leukemia, Lymphoma
- Interventions
- Thiotepa, Clofarabine, Busulfan, Allogeneic Stem Cell Transplantation, Thymoglobulin (ATG), G-CSF (Filgrastim), Tacrolimus, Methotrexate, Cyclophosphamide, Mesna
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer
- Interventions
- STM-416p
- Drug
- Lead sponsor
- SURGE Therapeutics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • Gainesville, Florida
- Conditions
- Prostate Cancer
- Interventions
- (64Cu)-NOTA-PSMAi-PEG-Cy5.5-C' dot tracer, PET/MRI/fluorescence imaging, Blood and urine sampling, laparoscopic radical prostatectomy and bilateral pelvic LN dissection or a salvage lymph node dissection, 89Zr-DFO-PSMAi-PEG-Cy5.5-C' dots
- Drug · Diagnostic Test · Other + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer
- Interventions
- pazopanib hydrochloride, therapeutic conventional surgery
- Drug · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Philadelphia, Pennsylvania
- Conditions
- Erectile Dysfunction
- Interventions
- Shockwave Therapy, SHAM shockwave therapy
- Device · Other
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 40 Years to 75 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy), Prostate Cancer, Prostate Cancer Patients Undergoing Radical Prostatectomy, High-risk Prostate Cancer
- Interventions
- FK-PC101, Standard of Care (SOC)
- Biological
- Lead sponsor
- Cellvax Therapeutics Inc
- Industry
- Eligibility
- Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Gahanna, Ohio • Myrtle Beach, South Carolina
- Conditions
- High Risk Prostate Carcinoma, Prostate Cancer
- Interventions
- Abiraterone acetate, Prednisone, Hyperpolarized [1-13C] pyruvate (HP 13C), Magnetic Resonance Imaging (MRI), Non-investigational radical prostatectomy (RP), Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) PET/Computerized tomography (CT)
- Drug · Procedure
- Lead sponsor
- Ivan de Kouchkovsky, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Healthy
- Interventions
- Radical 7, Radius 7
- Device
- Lead sponsor
- Pamela Petersen
- Other
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin